Early detection of Alzheimer's has long been the field's most urgent unsolved problem — treatments work best before widespread neurodegeneration occurs, yet current biomarker tools (PET imaging, cerebrospinal fluid analysis) are either expensive, invasive, or inaccessible at scale. A non-invasive electrophysiological signal measurable from the scalp during ordinary wakefulness could reshape that calculus entirely.
Researchers at INSERM's Institut du Cerveau identified a meaningful association between the amplitude of slow brain waves — recorded non-invasively via EEG at the scalp surface during wakefulness — and the accumulation of hallmark Alzheimer's lesions, specifically amyloid plaques and tau tangles. Crucially, this signal appears detectable at an early, pre-symptomatic stage, before cognitive decline becomes clinically apparent. The approach leverages standard electroencephalography equipment already widely deployed in neurology clinics, requiring no radioactive tracers or lumbar punctures.
This finding deserves careful contextual framing. EEG-based Alzheimer's research is not new — slowing of dominant brain rhythms and disruption of neural synchrony have been documented in symptomatic patients for decades. What distinguishes this INSERM work is the proposed link to pathological lesion burden in individuals who may not yet show overt impairment, pushing the detection window earlier. However, several critical questions remain open: the cohort size and composition, whether the association holds across diverse populations and comorbidities, the specificity of slow-wave amplitude changes to Alzheimer's versus other neurodegenerative or sleep-related conditions, and most importantly, whether this signal has predictive value in prospective longitudinal tracking. EEG amplitude is also sensitive to technical variables including electrode placement and vigilance state, complicating standardization across clinical sites. If replicated in larger, controlled trials, this biomarker approach could democratize Alzheimer's risk screening, particularly in low-resource settings where PET or CSF testing is unavailable — an incremental but potentially high-impact step toward population-level early intervention.
